Associated Genetic Biomarkers
IGH-CCND3 Fusion serves as an inclusion eligibility criterion in 3 clinical trials, of which 2 are open and 1 is closed. Of the trials that contain IGH-CCND3 Fusion as an inclusion criterion, 2 are phase 2 (1 open) and 1 is phase 3 (1 open).
Trials with IGH-CCND3 Fusion in the inclusion eligibility criteria most commonly target multiple myeloma and plasma cell leukemia .
Ixazomib, placebo, anti-cd19-car retroviral vector-transduced autologous t cells, autologous hematopoietic stem cell transplantation, and bortezomib are the most frequent therapies in trials with IGH-CCND3 Fusion as an inclusion criteria .
Significance of IGH-CCND3 Fusion in Diseases
Multiple Myeloma +
IGH-CCND3 Fusion is an inclusion criterion in 3 clinical trials for multiple myeloma, of which 2 are open and 1 is closed. Of the trials that contain IGH-CCND3 Fusion and multiple myeloma as inclusion criteria, 2 are phase 2 (1 open) and 1 is phase 3 (1 open) .
Plasma Cell Leukemia +
IGH-CCND3 Fusion is an inclusion criterion in 1 clinical trial for plasma cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains IGH-CCND3 Fusion and plasma cell leukemia as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.